Coronary Artery Disease After Heart Transplantation (ECP)
Coronary Artery Disease in Transplanted Heart (Diagnosis), Platelet Dysfunction
About this trial
This is an interventional treatment trial for Coronary Artery Disease in Transplanted Heart (Diagnosis) focused on measuring Heart Transplantation, Cardiac Allograft Vasculopathy
Eligibility Criteria
Inclusion Criteria:
- Age 18-100
- Informed and signed consent
- Positive Luminex analysis: Blood samples with DSA levels >3000 MFI
- Coronary angiography with evidence of CAV (ISHLT class ≥1) according to ISHLT criteria's.
Exclusion Criteria:
- Severe asthma or COLD with FEV1 < 50%*
- 2° or 3° AV block*
- Pregnancy
- Creatinine >250 mmol/l**
- Platelet count below 20 x 109/L
- History of allergy to 8-Methoxypsoralen (8-MOP)
History of light-sensitive disease
- These patients will not be subjected to adenosine submission **These patients will not be subjected to OCT evaluation
Control groups:
- 120 patients with angiographically proven coronary artery disease treated with 75 mg aspirin daily for at least seven days (no other antithrombotic drugs are allowed). These data is already available.
- 60 healthy subjects on no medication - samples are taken before and after 75 mg aspirin daily for at least seven days. These data is already available.
As the data regarding the control groups are already available from previous studies at our department, these control patients are no considered actively included in this study. Hence, the patient population consists of the 60 HTx patients.
Sites / Locations
- Aarhus Universitetshospital, Afdeling for HjertesygdommeRecruiting
Arms of the Study
Arm 1
Arm 2
Arm 3
Other
Experimental
No Intervention
Aspirin - single arm
Extracorporeal photopheresis
Control group
1 tablet of Aspirin 75 mg administered x 1 daily for 7 days.
All patients with HLA antibodies receive 4 ECP-treatments in 2 months.
The control group does not receive ECP-treatments, but blood samples are drawn at the same intervals as treatment group and CAG+OCT are also performed at baseline and 12 months follow up as the treatment group.